Biomarkers · Cardiometabolic
Apolipoprotein B to A1 Ratio (ApoB/ApoA1)
Lower values go with lower risk of death. No risk curve catalogued yet.
Published risk of death1.52×continuous ApoB/ApoA1 ratio, multivariable Cox (increment not reported) (95% CI 1.17–1.98) · MAFLD patients from NHANES III linked to the National Death Index, USA
What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
Measured changes in ApoB/ApoA1, study by study
2 effects with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| pharmacologic | Rosuvastatin 10, 20 then 40 mg/day for 6 weeks each in patients with type 2 diabetes on oral agents or insulin (CORALL study) | ApoB/apoA1 ratio reduced by 34.9%, 39.2% and 40.5% after 6 weeks each on 10, 20 and 40 mg (baseline 0.86) | RCT | Wolffenbuttel BH, et al. Journal of internal medicine. 2005… |
What else moves this marker
They describe those study groups, not an individual, and an association is not a cause.
Diseases and conditions
| What | Effect on the marker | Comparison · population | Source |
|---|---|---|---|
| ↑ Acute ischemic (non-embolic) stroke, elderly · First-ever acute ischemic non-embolic stroke vs volunteers without CVD, age >70 | +0.18 ratio | Stroke 1.04 +/- 0.33 vs controls 0.86 +/- 0.22 (difference by subtraction) · Elderly (>70 y) stroke patients (n=163) and controls (n=166) | case control · PMID 20538481 |